Bioverge Ventures

EnClear Therapies, Inc. is a life sciences company based in Newburyport, Massachusetts, focused on developing device-based therapies for neurodegenerative diseases. The company specializes in the delivery and monitoring of cerebrospinal fluid (CSF) and has created a proprietary therapeutic platform aimed at removing toxic proteins from the CSF. EnClear's products are primarily designed to improve the lives of patients suffering from conditions such as Amyotrophic Lateral Sclerosis (ALS) and Progressive Supranuclear Palsy (PSP). By providing innovative solutions in the treatment of these neurological diseases, EnClear Therapies aims to help halt disease progression and extend patient lifespans.

Established in 2016, UBERDOC is a Boston-based digital platform that connects patients with top medical specialists for expedited appointments at transparent, affordable prices. Founded by Dr. Paula Muto, the company offers a user-friendly mobile application that allows patients to search by medical specialty, book appointments, and pay directly, eliminating the need for insurance paperwork and referrals. The platform operates on a direct-pay model, charging a $50 transaction fee to secure an appointment and an additional $250 once the consultation is completed. UBERDOC's innovative approach has attracted thousands of doctors across the United States, providing patients with immediate access to healthcare services while ensuring doctors receive prompt payment through the platform. UBERDOC's commitment to transparency and efficiency has established it as a recognized entity in the digital health community, participating in various industry conferences nationwide.

My Diabetes Tutor is a provider of diabetes education telehealth services, recently recognized as the first accredited diabetes education program in California by the American Association of Diabetes Educators. The organization aims to improve access to high-quality diabetes education for individuals with type 1, type 2, and gestational diabetes, as well as those in pre-diabetic states. By focusing on preventive medicine and health promotion, My Diabetes Tutor equips patients with the knowledge and skills necessary to modify their behavior and effectively manage their diabetes and related health conditions. The company has also contributed to the scientific community, presenting research at the American Diabetes Association Scientific Meeting and having its findings published in the Diabetes Journal.

Modulo Bio simulates the neuroimmune system to find medication candidates that target microglia cells. The organization's proprietary neuroimmune platform combines the most recent developments in stem cell biology and neuroscience with software, automation, and artificial intelligence to create novel treatments.

JelikaLite specializes in developing medical equipment for children with autism spectrum disorders, focusing on non-invasive methods to enhance brain health. Their primary product is a wearable device that integrates infrared light, EEG sensors, and an artificial intelligence personalization platform. This therapeutic device aims to reduce the symptoms of autism by promoting improvements in speech, decreasing anxiety, and enhancing responsiveness in pediatric patients. By utilizing innovative therapies, JelikaLite seeks to provide lasting benefits for children dealing with autism, emphasizing a commitment to advancing pediatric neurological health.

Eigen Therapeutics is a biotechnology company dedicated to developing innovative therapies that enhance the detection and treatment of cancer. The company specializes in "priming" therapies, which help targeted treatments become more effective by addressing cancer heterogeneity and increasing the vulnerability of cancer cells, while simultaneously improving the resilience of healthy cells. Eigen is creating a high-throughput discovery platform that combines biology and engineering, utilizing proprietary machine learning algorithms to identify new drug classes and therapeutic approaches. This platform incorporates robotic systems, laboratory operations software, and machine learning analysis pipelines, all developed in-house. By focusing on combination therapeutics that improve efficacy and reduce toxicity, Eigen aims to provide physicians with access to novel treatments for patients with unmet medical needs, ultimately striving to enhance patient outcomes and save lives.

GigaMune, established in 2017 as a spin-out from GigaGen, specializes in the development of advanced T cell therapies for cancer treatment. The company leverages its unique insights into T cell responses to tumors, combined with innovative techniques for massively parallel T cell receptor (TCR) discovery. GigaMune's technology facilitates the identification of anti-tumor payloads through extensive sequence searches and high-throughput screening, while also incorporating novel viruses for effective payload delivery. This approach aims to empower health professionals with efficient and targeted therapies to combat cancer.

Notable Labs, Inc. is a clinical-stage company that specializes in personalized lab testing services for cancer patients, particularly those with brain cancer. Founded in 2014 and based in Foster City, California, the company utilizes its proprietary Predictive Precision Medicines Platform to conduct drug combination experiments on patients' tumors. This platform allows Notable Labs to simulate cancer treatments and predict patient responses to specific therapies, enabling healthcare providers to prioritize combinations of FDA-approved treatments that can be prescribed without the need for clinical trials. By providing detailed reports to physicians, Notable Labs aims to enhance treatment efficacy and expedite therapeutic development for patients.

Foresight Mental Health is a technology-driven provider of psychiatry and therapy services, operating a network of clinics dedicated to mental health and wellness. The company employs a diverse team that includes psychiatrists, therapists, and psychiatric nurse practitioners who deliver care directly to patients. Foresight enhances its treatment offerings through innovative technology developed in collaboration with software and biomedical engineers, aimed at transforming the mental healthcare experience. By utilizing comprehensive patient profiles and a database of scientific research, the company conducts detailed analyses that include genetic profiles and assessments of brain-chemical balance. This holistic approach enables Foresight to offer tailored treatments, ultimately helping patients achieve improved mental health and overall well-being.

Octant Bio is a biotechnology company focused on developing synthetic technology aimed at enhancing health and treating diseases. The company employs a platform that integrates synthetic biology, genome engineering, next-generation sequencing, and computational tools to measure the activity of thousands of receptor pathways in human cells. This advanced technology allows scientists to utilize machine learning techniques to engineer small molecules capable of interacting with multiple receptors, thereby creating new possibilities for the treatment of complex diseases.

Alto Neuroscience is a clinical-stage biopharmaceutical company focused on improving mental health treatment through personalized medicine. By utilizing an AI-enabled biomarker platform, Alto integrates detailed patient data regarding brain activity and behavior to develop effective therapeutics for specific populations. The company aims to transform the traditional trial-and-error approach in psychiatry by matching the appropriate treatment to individual patients, thereby enhancing the effectiveness of interventions. Alto's clinical-stage assets include various products targeting conditions such as depressive disorders and schizophrenia, identified through independent brain-based biomarkers. Through its innovative approach, Alto Neuroscience seeks to redefine psychiatric care at a critical time for mental health.

Bionaut Labs, Inc. is a biotechnology company based in Palo Alto, California, founded in 2016. The company specializes in developing a novel intra-tissue navigation platform utilizing Bionaut nano/micro robots that operate within the body. This innovative technology enables precise anatomical targeting for the treatment of central nervous system disorders, offering a new approach to precision medicine. By employing remote-controlled micro-robots, Bionaut Labs enhances the development of therapeutics, making advanced technologies like gene therapy and CRISPR-Cas9 feasible in challenging clinical scenarios. The Bionaut platform allows medical professionals to access any anatomic location within the body, facilitating the automation of complex procedures while eliminating the need for external incisions, thereby improving patient outcomes for those with limited treatment options.

Eigen Therapeutics is a biotechnology company dedicated to developing innovative therapies that enhance the detection and treatment of cancer. The company specializes in "priming" therapies, which help targeted treatments become more effective by addressing cancer heterogeneity and increasing the vulnerability of cancer cells, while simultaneously improving the resilience of healthy cells. Eigen is creating a high-throughput discovery platform that combines biology and engineering, utilizing proprietary machine learning algorithms to identify new drug classes and therapeutic approaches. This platform incorporates robotic systems, laboratory operations software, and machine learning analysis pipelines, all developed in-house. By focusing on combination therapeutics that improve efficacy and reduce toxicity, Eigen aims to provide physicians with access to novel treatments for patients with unmet medical needs, ultimately striving to enhance patient outcomes and save lives.

Circularis Biotechnologies, Inc. is a biotechnology company focused on developing innovative methods to regulate gene expression, aiming to enhance the production yields of biotherapeutics. Founded in 2014 and based in Oakland, California, the company offers a range of products and services, including RACRE Variant Libraries, hCMV Variant Library, Protein expression with CMV promoters, and T7 Variant Library. Additionally, Circularis provides services such as RACRE Enhancement, RACRE Discovery, RACRE Technology Access Program, and Ribozyme Analysis of Cis-Regulatory Elements. Through its technology, Circularis Biotechnologies seeks to advance the capabilities of biotherapeutic production in the industry.

Ochre Bio Ltd is a biotechnology company focused on developing genomic medicines to improve outcomes for liver transplant patients. Established in 2019 and headquartered in Headington, United Kingdom, the company specializes in rejuvenating donor livers before transplantation, ensuring that more patients in need of a new liver receive one. Utilizing advanced genomic techniques, Ochre Bio identifies and targets over-active genes that contribute to liver diseases. The company tests its novel RNA-based therapies on discarded donor livers kept alive outside the body, allowing for direct evaluation of treatment efficacy. With roots in over 15 years of liver genomics research, Ochre Bio aims to address liver-related conditions and enhance the availability of healthy livers for transplantation.

NutriSense, Inc. is a health and wellness platform that specializes in monitoring blood glucose levels in real-time using continuous glucose monitoring (CGM) technology and a dedicated tracking application. Founded in 2019 and based in Chicago, Illinois, the company focuses on personalizing nutrition through advanced machine learning techniques. NutriSense offers corporate wellness programs, along with a glucose sensor and app for diet tracking, as well as access to personal dietitians. The company's mission is to empower individuals to discover and achieve their health potential by providing tailored insights into their nutritional habits.

BioROSA Technologies Inc. is a Belmont, Massachusetts-based company focused on developing blood tests for Autism Spectrum Disorders (ASD). Founded in 2018, the company aims to establish a biologically-based standard of care for ASD through innovative diagnostic tools. These tools enable clinicians to identify individuals at risk for ASD by utilizing blood-based biomarkers and advanced machine learning techniques. BioROSA’s platform not only enhances early detection and diagnosis but also supports therapeutic developments by facilitating patient stratification and assessing pharmacodynamics in clinical trials. This comprehensive approach equips healthcare professionals with the necessary resources to improve patient outcomes through timely intervention.

Juno Diagnostics, Inc. is a health technology company based in San Diego, California, that specializes in cell-free DNA-based prenatal testing. Founded in 2017, the company aims to democratize access to genetic information by developing simple, cost-effective devices for point-of-need genetic testing. Juno's technology allows for noninvasive prenatal tests that enhance sample collection and provide high-quality test results without the challenges associated with traditional testing methods, such as high costs, long lead times, and the need for phlebotomy. In addition to prenatal testing, Juno is also involved in developing genetic testing tools and applications in areas such as epigenetics, inherited diseases, and cancer diagnostics.

HepaTx Corporation, founded in 2015 and based in Palo Alto, California, specializes in developing regenerative medicine solutions for liver diseases. The company focuses on creating therapies that address the urgent need for improved treatments for life-threatening liver conditions. Utilizing technology developed at Stanford University, HepaTx is working on efficient production of hepatocytes for therapeutic use. These therapies aim to replace lost liver function in patients suffering from end-stage liver disease, offering a potential alternative to whole organ transplants. By leveraging principles of regenerative medicine, HepaTx's approach seeks to enable the body to repair damaged tissues and organs, thereby providing physicians with innovative tools to treat previously untreatable patients in a more cost-effective manner.

Juno Diagnostics, Inc. is a health technology company based in San Diego, California, that specializes in cell-free DNA-based prenatal testing. Founded in 2017, the company aims to democratize access to genetic information by developing simple, cost-effective devices for point-of-need genetic testing. Juno's technology allows for noninvasive prenatal tests that enhance sample collection and provide high-quality test results without the challenges associated with traditional testing methods, such as high costs, long lead times, and the need for phlebotomy. In addition to prenatal testing, Juno is also involved in developing genetic testing tools and applications in areas such as epigenetics, inherited diseases, and cancer diagnostics.

Elucid, located in the Boston biotech and medtech hub, specializes in enhancing the accuracy and cost-effectiveness of cardiovascular diagnostic imaging through machine learning. Its flagship product, ElucidVivo, is the first FDA-cleared software that evaluates plaque vulnerability from a single computed tomography angiography (CTA) scan, aiding in the assessment of heart attack and stroke risk as well as treatment selection. The company also collaborates with pharmaceutical firms, healthcare providers, and research organizations to offer quantitative image analysis services. By applying artificial intelligence to vascular diagnostics, Elucid aims to improve patient outcomes while providing a non-invasive and economically efficient means of capturing critical health information, thereby supporting cardiovascular pathologists in delivering comprehensive clinical insights.

IVIVA Medical focuses on developing autologous tissue constructs to address end-stage renal disease (ESRD), a condition affecting over 500,000 patients in the United States. As transplant remains the only definitive treatment for ESRD, the majority of patients do not receive donor kidneys. The company utilizes advanced technologies in tissue engineering, 3D additive manufacturing, and stem cell biology to create bioartificial platforms that not only provide therapeutic solutions but also lay the groundwork for future engineered functional tissues. Through these innovations, IVIVA aims to contribute to the field of regenerative medicine and help alleviate the shortage of donor organs.

Ancilia Biosciences focuses on developing engineered bacterial therapies aimed at treating diseases associated with the microbiome. The company specializes in creating virus-resistant live bacterial products that modulate the human microbiome, specifically targeting the viral components within the gut microbiome. By concentrating on healthy gut bacteria and their predatory phages, Ancilia engineers resistant bacterial strains to combat diseases. Its innovative approach includes the development of a new class of live biotherapeutics that allows medical professionals to target specific phages or viruses that induce lysis, with applications in immunology and oncology.

Repair Biotechnologies, Inc. is a biotechnology company focused on developing innovative treatments aimed at reversing immunosenescence and atherosclerosis associated with aging. Founded in 2018 and based in Syracuse, New York, the company utilizes a cholesterol-degrading platform to create therapies that target conditions driven by excess or modified cholesterol, such as atherosclerosis and familial hypercholesterolemias. Through its gene therapy and recombinant protein approaches, Repair Biotechnologies seeks to address significant age-related health issues by treating the underlying causes of these medical conditions. The company's emphasis on safety and tolerability enhances its commitment to improving patient outcomes.

Octagon Therapeutics, Inc. is a preclinical-stage biopharmaceutical company based in Cambridge, Massachusetts, focused on developing innovative antibiotic medicines for life-threatening autoimmune diseases such as Pemphigus Vulgaris, Systemic Lupus, and Multiple Sclerosis. Founded in 2016, the company is dedicated to addressing multi-drug resistant infections and has shown effectiveness against critical pathogens identified by the World Health Organization. Octagon's targeted immunomodulator medicines aim to restore immune balance in patients with chronic autoimmune and inflammatory conditions by selectively targeting dysregulated immune cells, thereby helping patients avoid chronic immunosuppression. The company's operations are supported by a state-of-the-art facility adjacent to Harvard University, enabling efficient development of its therapies with minimal overhead. The management team comprises experienced scientists, clinicians, and entrepreneurs, contributing to a growing pool of research talent dedicated to advancing drug development.

Circularis Biotechnologies, Inc. is a biotechnology company focused on developing innovative methods to regulate gene expression, aiming to enhance the production yields of biotherapeutics. Founded in 2014 and based in Oakland, California, the company offers a range of products and services, including RACRE Variant Libraries, hCMV Variant Library, Protein expression with CMV promoters, and T7 Variant Library. Additionally, Circularis provides services such as RACRE Enhancement, RACRE Discovery, RACRE Technology Access Program, and Ribozyme Analysis of Cis-Regulatory Elements. Through its technology, Circularis Biotechnologies seeks to advance the capabilities of biotherapeutic production in the industry.

Volumetric, Inc. is a Houston-based company that specializes in advanced biomaterials and biofabrication through its innovative 3D bioprinting platform. Founded in 2014, Volumetric focuses on creating vascularized human tissue and developing bioprinters and bio inks for a range of applications, including life sciences, drug discovery, and medical devices. The company's technology aims to enhance research in biomaterials, cancer treatments, and the potential replacement of human organs, positioning it at the forefront of developments in regenerative medicine and tissue engineering.

Pragma Bio is a biotechnology company focused on developing microbiome-based therapies for cancer and autoimmune diseases. Founded in 2018 in Millbrae, California, by Peter McCaffrey, Kovi Bessoff, Ayin Vala, and Kareem Barghouti, the company utilizes proprietary genomic sequencing, artificial intelligence, and synthetic biology techniques to identify biomarkers and therapeutics for complex immunologic disorders. Its innovative platform aggregates extensive public and private data to create a microbiome database, enabling the discovery of connections between biologically relevant data. By using this analytical approach, Pragma Bio aims to identify novel biomarkers that can help stratify patient risk and predict clinical outcomes. The company emphasizes the importance of understanding the gut-immune axis and employs machine learning to enhance the drug discovery process, offering a more efficient alternative to traditional methods and aiming to deliver improved medicines to patients more rapidly and cost-effectively.

Contraline, Inc. is a biotechnology company based in Charlottesville, Virginia, focused on developing male birth control solutions. The company is creating an innovative, long-lasting, non-hormonal, and reversible contraceptive known as Echo-V. This product consists of an ultrasound-visible polymer solution that is injected into the vas deferens, forming a polymer hydrogel device. This device acts as a semi-permeable membrane, effectively blocking sperm while allowing bodily fluids to pass through. Contraline also offers Vasintomy, a non-surgical procedure for the insertion of Echo-V, providing a cost-effective and user-friendly approach to male contraception. Founded in 2015, Contraline aims to transform male reproductive health through its groundbreaking technology.

RockStep Solutions is a developer of cloud-based laboratory management software aimed at enhancing data and operational efficiency in drug discovery. Its flagship product, Climb, addresses the challenges of data chaos and operational inefficiencies that hinder return on investment in drug research. The platform is designed for use by pharmaceutical companies, biotechs, contract research organizations (CROs), and academic institutions, enabling these users to manage in vivo studies and laboratory data effectively. Climb offers features such as data assurance, access control, and security, allowing researchers to access and track their data seamlessly from any laptop or mobile device. By reducing data silos and improving collaboration, RockStep Solutions facilitates a more efficient path to market for new drug discoveries.

Excision BioTherapeutics Inc. is a life science company based in Philadelphia, Pennsylvania, established in 2015. The company specializes in developing gene editing therapeutics aimed at treating life-threatening diseases caused by neurotropic viruses. Utilizing CRISPR-based technology, Excision BioTherapeutics focuses on creating advanced gene-editing medicines that can eradicate or disrupt viral genes in human patients. The company is committed to advancing these therapeutics to ensure they are safe and effective, with the goal of significantly improving the lives of individuals affected by viral infections worldwide.

EnClear Therapies, Inc. is a life sciences company based in Newburyport, Massachusetts, focused on developing device-based therapies for neurodegenerative diseases. The company specializes in the delivery and monitoring of cerebrospinal fluid (CSF) and has created a proprietary therapeutic platform aimed at removing toxic proteins from the CSF. EnClear's products are primarily designed to improve the lives of patients suffering from conditions such as Amyotrophic Lateral Sclerosis (ALS) and Progressive Supranuclear Palsy (PSP). By providing innovative solutions in the treatment of these neurological diseases, EnClear Therapies aims to help halt disease progression and extend patient lifespans.

Foresight Mental Health is a technology-driven provider of psychiatry and therapy services, operating a network of clinics dedicated to mental health and wellness. The company employs a diverse team that includes psychiatrists, therapists, and psychiatric nurse practitioners who deliver care directly to patients. Foresight enhances its treatment offerings through innovative technology developed in collaboration with software and biomedical engineers, aimed at transforming the mental healthcare experience. By utilizing comprehensive patient profiles and a database of scientific research, the company conducts detailed analyses that include genetic profiles and assessments of brain-chemical balance. This holistic approach enables Foresight to offer tailored treatments, ultimately helping patients achieve improved mental health and overall well-being.

Ombre is a provider of microbiome testing kits that focus on personalized health solutions. The company offers subscription-based services that include customized microbiome testing and probiotics tailored to individual needs. Through its testing kits, Ombre delivers actionable insights aimed at preventing chronic diseases such as obesity, cystic fibrosis, and Alzheimer's. By addressing the root causes of gut-related issues, Ombre empowers customers to improve their overall health and well-being with science-backed interventions.

Suggestic, Inc. is a San Francisco-based company founded in 2014 that specializes in automated and personalized lifestyle and nutrition coaching. Its platform leverages proprietary artificial intelligence to create tailored diet plans that cater to users' individual goals, dietary preferences, and restrictions. The application facilitates precision eating by offering personalized meal plans, smart shopping lists, recipe suggestions, and restaurant recommendations. By encoding dietary programs as rulesets, Suggestic enables health-related organizations to efficiently build and deliver customized nutrition programs through white label solutions or direct API integration. The platform also supports data acquisition from users through assessments and lab tests, allowing it to provide relevant food recommendations that assist individuals in weight management, enhancing vitality, and preventing or reversing chronic diseases.

Ombre is a provider of microbiome testing kits that focus on personalized health solutions. The company offers subscription-based services that include customized microbiome testing and probiotics tailored to individual needs. Through its testing kits, Ombre delivers actionable insights aimed at preventing chronic diseases such as obesity, cystic fibrosis, and Alzheimer's. By addressing the root causes of gut-related issues, Ombre empowers customers to improve their overall health and well-being with science-backed interventions.

Intelligent Implants, founded in 2014 in Cork, Ireland, specializes in the development of wireless implantable electronics designed to stimulate, steer, and monitor bone growth. The company focuses on creating electrotherapeutic devices that not only treat diseases but also support the recovery of bone and other tissues. By integrating data, engineering, and medicine, Intelligent Implants aims to deliver innovative, active, and connected medical devices that enhance patient treatment and facilitate decision-making for healthcare professionals. Their technology allows for the acceleration and adjustment of bone growth, enabling healthcare providers to effectively utilize electrotherapeutics to monitor and control patient conditions, ultimately leading to more timely and informed medical interventions.

Leucadia Therapeutics Inc is a privately-held, pre-clinical stage company based in Riverside, California, dedicated to developing innovative solutions for Alzheimer's disease prevention and treatment. The company's primary product, Arethusta, is an implantable device designed to restore cerebrospinal fluid flow across the cribriform plate, thereby enhancing the clearance of toxic metabolites from the brain's earliest affected regions. In addition to its device, Leucadia Therapeutics is also working on a diagnostic algorithm that utilizes big data to assess Alzheimer's disease risk. Through these advancements, the company aims to provide effective interventions for Alzheimer's disease and improve patient outcomes.

OccamzRazor specializes in enhancing drug discovery and development through the integration of machine learning and advanced biological techniques. The company's innovative analysis pipeline employs two proprietary technologies, Panoramic AI and RazorBrain, which work together to extract valuable data from both unstructured sources, such as biomedical publications and patient-reported outcomes, and structured datasets, including genomics and proteomics. This comprehensive approach allows for the generation of robust drug discovery hypotheses and insights. OccamzRazor has successfully applied its platform to various applications, including biomedical text data extraction, novel target identification, and drug repurposing. Furthermore, the company is focused on developing a neuroscience therapeutics platform aimed at addressing Parkinson's Disease by creating an exhaustive knowledge graph that synthesizes existing biomedical data, ultimately supporting healthcare professionals in therapeutic strategy and drug development.

EnClear Therapies, Inc. is a life sciences company based in Newburyport, Massachusetts, focused on developing device-based therapies for neurodegenerative diseases. The company specializes in the delivery and monitoring of cerebrospinal fluid (CSF) and has created a proprietary therapeutic platform aimed at removing toxic proteins from the CSF. EnClear's products are primarily designed to improve the lives of patients suffering from conditions such as Amyotrophic Lateral Sclerosis (ALS) and Progressive Supranuclear Palsy (PSP). By providing innovative solutions in the treatment of these neurological diseases, EnClear Therapies aims to help halt disease progression and extend patient lifespans.

Blue Mesa Health Inc. is a digital therapeutics company focused on diabetes prevention through its platform, Transform. Founded in 2015 and based in New York, the company provides a comprehensive solution that combines health coaching and behavioral support to help users reverse prediabetes. Transform leverages advances in technology and behavioral psychology to deliver preventive health coaching in a flexible digital format. Blue Mesa Health aims to address the growing burden of chronic diseases, which account for a significant portion of deaths and healthcare costs in the United States and globally. In 2018, the company expanded its reach by launching its product in Latin America and the Middle East, positioning itself as a leader in culturally diverse, technology-driven behavioral change programs. As of January 2020, Blue Mesa Health operates as a subsidiary of Virgin Pulse, Inc.

Blue Mesa Health Inc. is a digital therapeutics company focused on diabetes prevention through its platform, Transform. Founded in 2015 and based in New York, the company provides a comprehensive solution that combines health coaching and behavioral support to help users reverse prediabetes. Transform leverages advances in technology and behavioral psychology to deliver preventive health coaching in a flexible digital format. Blue Mesa Health aims to address the growing burden of chronic diseases, which account for a significant portion of deaths and healthcare costs in the United States and globally. In 2018, the company expanded its reach by launching its product in Latin America and the Middle East, positioning itself as a leader in culturally diverse, technology-driven behavioral change programs. As of January 2020, Blue Mesa Health operates as a subsidiary of Virgin Pulse, Inc.

Ligandal Inc. is a biotechnology company based in Oakland, California, focused on developing therapeutic nanotechnologies for precision medicine. Founded in 2013 and originally named Ligandal Technology LLC, the company specializes in creating a delivery platform aimed at curing and treating diseases through advanced gene therapies. Ligandal's technology utilizes a ligand discovery engine to design materials that can transport a variety of nucleic acids and proteins, including CRISPR and mRNA, to specific cell types with high accuracy. Their innovative approach incorporates peptide-based technologies for gene therapy, gene editing, regenerative medicine, and immunotherapy. Ligandal's initial applications of its technology target areas such as hematology, immuno-oncology, and infectious diseases, facilitating precise delivery of genetic materials and improving therapeutic outcomes.

Notable Labs, Inc. is a clinical-stage company that specializes in personalized lab testing services for cancer patients, particularly those with brain cancer. Founded in 2014 and based in Foster City, California, the company utilizes its proprietary Predictive Precision Medicines Platform to conduct drug combination experiments on patients' tumors. This platform allows Notable Labs to simulate cancer treatments and predict patient responses to specific therapies, enabling healthcare providers to prioritize combinations of FDA-approved treatments that can be prescribed without the need for clinical trials. By providing detailed reports to physicians, Notable Labs aims to enhance treatment efficacy and expedite therapeutic development for patients.

Echo is a provider of am automated microscope intended for biological research and pathologies. The company's product provides features like inverted images, cell counting, phase contrast, brightfield and fluorescence, enabling customers to have accurate images at a lower cost.

CrowdMed, Inc. operates an online platform that utilizes prediction market technology to assist patients in diagnosing complex medical conditions. Founded in 2012 and based in San Francisco, CrowdMed connects patients with a network of medical detectives, including licensed physicians, medical students, and other healthcare professionals, to collaboratively solve challenging medical cases. By leveraging the collective intelligence of thousands of contributors, the platform provides patients with insightful diagnostic suggestions for their unresolved symptoms. This approach not only aims to expedite the diagnostic process for individuals who have struggled with chronic health issues but also seeks to reduce healthcare costs while maintaining quality care. CrowdMed's innovative model positions it as a trusted resource for patients seeking clarity and solutions in their healthcare journeys.

Echo is a provider of am automated microscope intended for biological research and pathologies. The company's product provides features like inverted images, cell counting, phase contrast, brightfield and fluorescence, enabling customers to have accurate images at a lower cost.

Echo, we believe health is about people, not pills. That’s why we’ve created a new kind of pharmacy. One that comes to you, not the other way around. We start with being brilliant at fulfilling prescriptions because getting people taking the right medicine is the first step in staying well. But there’s more we can do. It’s not just patients we support, its partners. Together with other like-minded pharmacies, GPs and prescribing services we deliver even more positive experiences. Ultimately, we want to help patients understand and do more for themselves, so together they can make the right decisions with their GPs. And when it comes time to improve our health, we all know more Technology should make the future of health care more human. So ours comes packed with care.

Notable Labs, Inc. is a clinical-stage company that specializes in personalized lab testing services for cancer patients, particularly those with brain cancer. Founded in 2014 and based in Foster City, California, the company utilizes its proprietary Predictive Precision Medicines Platform to conduct drug combination experiments on patients' tumors. This platform allows Notable Labs to simulate cancer treatments and predict patient responses to specific therapies, enabling healthcare providers to prioritize combinations of FDA-approved treatments that can be prescribed without the need for clinical trials. By providing detailed reports to physicians, Notable Labs aims to enhance treatment efficacy and expedite therapeutic development for patients.